Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) EBT Margin (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of EBT Margin data on record, last reported at 18289.8% in Q3 2025.

  • For Q3 2025, EBT Margin fell 966036.0% year-over-year to 18289.8%; the TTM value through Sep 2025 reached 8633.11%, down 472081.0%, while the annual FY2024 figure was 3499.78%, 950363.0% up from the prior year.
  • EBT Margin reached 18289.8% in Q3 2025 per BTAI's latest filing, down from 16536.67% in the prior quarter.
  • Across five years, EBT Margin topped out at 449600.0% in Q1 2022 and bottomed at 25348.06% in Q1 2023.
  • Average EBT Margin over 4 years is 20711.42%, with a median of 8013.69% recorded in 2025.
  • Peak YoY movement for EBT Margin: tumbled -47494806bps in 2023, then soared 2073930bps in 2024.
  • A 4-year view of EBT Margin shows it stood at 23052.94% in 2022, then surged by 73bps to 6231.12% in 2023, then surged by 40bps to 3740.44% in 2024, then crashed by -389bps to 18289.8% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 18289.8% in Q3 2025, 16536.67% in Q2 2025, and 8013.69% in Q1 2025.